硼替佐米增加耐药白血病细胞株K562/DNR对化疗药物的敏感性  

Bortezomib sensitizes leukemia drug-resistant cell line K562/DNR to chemical durgs

作　　者：李迎春[1] 王慧涵 李佳[1] 廖爱军[1] 张嵘[1] 吴斌[1] 刘卓刚[1] 杨威[1] 

机构地区：[1]中国医科大学附属盛京医院血液科,辽宁沈阳110022

出　　处：《现代肿瘤医学》2013年第3期474-477,共4页Journal of Modern Oncology

基　　金：辽宁省教育厅课题(编号:20060985)

摘　　要：目的:观察蛋白酶体抑制剂硼替佐米是否可以增加耐药白血病细胞株K562/DNR对化疗药物的敏感性。方法:MTT法计算硼替佐米逆转耐药倍数,流式细胞术(FCM)检测细胞调亡比及细胞内药物浓度。结果:表柔比星单独及联合硼替佐米作用于K562/DNR细胞株的IC50分别为417.0μg/ml和210.4μg/ml,逆转倍数为1.98倍;柔红霉素单独及联合硼替佐米作用于K 562/DNR细胞株的IC50分别为457.7μg/ml和324.9μg/ml,逆转倍数为1.4倍。单独应用表柔比星组细胞调亡比为(28.74±4.6)%,联合硼替佐米组细胞调亡比为(39.14±9.6)%。硼替佐米能使K562/DNR细胞内柔红霉素含量增加,而对K562/S细胞无类似影响。结论:蛋白酶体抑制剂硼替佐米能增加耐药白血病细胞株K562/DNR的化疗药物的敏感性,逆转耐药性。Objective：To observe whether proteasome inhibitor bortezomib could sensitize leukemia drug - resist- ant cell line K562/DNR to chemical durgs. Methods：Resistance reverse fold of bortezomib was calculated according to MTT assay,and apoptosis rates of cells and durg concentration were observed by flow cytometry. Results： IC50 of pharmorubicin alone and in combination with bortezomib on K562/DNR was 417.01μg/ml and 210.4μg/ml respec- tively,and reverse fold was 1.98;IC50 of daunorubicin alone and in combination of bortezomib on K562/DNR was 457.7μg/ml,and 324.9μg/ml respectively and reverse fold was 1.4. Apoptosis under treatment of pharmorubicin a- lone and in combination of bortezomib was （28.74± 4.6） % and （39.14 ± 9.6） % respectively. Bortezomib couldincrease intracellular daunorubicin amount of K562/DNR and had no similar influence on K562/S. Conclusion：Pro- teasome inhibitor bortezomib could sensitize leukemia drug - resistant cell line K562/DNR to chemical durgs and re- verse durg resistance.

关 键 词：硼替佐米 耐药 凋亡 白血病 

分 类 号：R73-361[医药卫生—肿瘤] R733.71[医药卫生—临床医学]